BIOLOGICAL DEFENSE: Additional Information That Congress May Find Useful as It Considers DOD's Advanced Development and Manufacturing Capability

Abstract

DOD has long expressed concerns about its ability to acquire and maintain the capability to research, develop, and manufacture medical countermeasures (e.g., vaccines) against biological warfare threat agents, toxins, and endemic diseases. In 2013, DOD partnered with a private-sector biopharmaceutical company to develop an ADM facility with the capability to use disposable equipment enabling timely changes in a production line for medical countermeasures. The facility was fully operational in March 2017,and DOD can now renew its contract for 2-year periods through 2024.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2017
Accession Number
AD1164004

Entities

People

  • Joseph W. Kirschbaum

Organizations

  • United States Government Accountability Office

Tags

DTIC Thesaurus Topics

  • Biological Products
  • Business Administration
  • Congress
  • Contracts
  • Cost Analysis
  • Cost Benefit Analysis
  • Department Of Defense
  • Disposable Equipment
  • Governments
  • House Of Representatives
  • Infectious Diseases
  • Intellectual Property
  • Manufacturing
  • Medical Countermeasures
  • Medical Personnel
  • National Governments
  • National Security
  • Procurement
  • Public Health
  • United States
  • United States Government
  • Vaccines

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.
  • Government and Public Administration Law.

Technology Areas

  • Biotechnology